Year None20222021202020192018201720162015201420122011201020092008

May 19, 2022

Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022

May 16, 2022

Albireo Reports Q1 2022 Financial Results and Business Update

May 9, 2022

Albireo to Report Q1 2022 Financial Results on May 16

March 29, 2022

Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome

March 1, 2022

Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update

February 22, 2022

Albireo to Report Q4 and Year-End 2021 Financial Results on March 1

February 22, 2022

NICE Recommends Albireo’s Bylvay® (odevixibat) for All PFIC Types

February 14, 2022

Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease

January 5, 2022

Albireo Increases 2021 Bylvay™ (odevixibat) Sales Guidance

• Email Alerts
• RSS
• Print